Radium-223 chloride: a potential new treatment for castration-resistant prostate cancer patients with metastatic bone disease

• DOI: 10.2147/cmar.s25537
• Publication Date: 2013-01-08T23:33:15Z
• Authors: Harrison; Daniel George; Wong; Andrew Armstrong
• Keywords: Zoledronic Acid; Radium-223; Denosumab

Radium-223 chloride ((223)Ra; Alpharadin) is an alpha-emitting radioisotope that targets areas of osteoblastic metastasis and excreted by the small intestine. When compared with beta-emitters (eg, strontium-89, samarium-153), (223)Ra delivers a high quantity energy per track length short tissue penetration.This review describes mechanism, radiobiology, preclinical development discusses clinical data currently available regarding its safety efficacy profile.Data from trials including abstracts were collected reviewed using PubMed Database, as well American Society Clinical Oncology abstract database.Current bone-targeted therapies fall into two main categories: antiresorptive agents zoledronic acid, denosumab), which have been shown to delay skeletal-related events, radiopharmaceuticals may role in pain palliation. Historically, neither nor definitive evidence improved overall survival or other antitumor effects metastatic castrate-resistant prostate cancer (mCRPC). Radiopharmaceuticals are limited myelosuppresion, thrombocytopenia, renal excretion. In recently reported randomized Phase III trial men symptomatic bone-metastatic CRPC who had received ineligible for docetaxel chemotherapy, treatment resulted delayed events. Toxicity consisted minor gastrointestinal side mild neutropenia thrombocytopenia rarely severe. Pending regulatory approval, represent unique distinct option important subgroup patients mCRPC; future should address use combination sequence existing novel agents.